US7626192B2
(en)
|
1997-05-27 |
2009-12-01 |
State of Oregon Acting by the Through the State Board of Higher Education on Behalf of the University of Oregon |
Scaffold-organized clusters and electronic devices made using such clusters
|
US6673901B2
(en)
*
|
1997-06-12 |
2004-01-06 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
US6818418B1
(en)
*
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
US7115396B2
(en)
*
|
1998-12-10 |
2006-10-03 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
AU2001249459A1
(en)
*
|
2000-03-24 |
2001-10-08 |
The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon |
Scaffold-organized clusters and electronic devices made using such clusters
|
US8263741B2
(en)
|
2000-07-11 |
2012-09-11 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
WO2002032925A2
(en)
*
|
2000-10-16 |
2002-04-25 |
Phylos, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
US7598352B2
(en)
*
|
2000-11-17 |
2009-10-06 |
University Of Rochester |
Method of identifying polypeptide monobodies which bind to target proteins and use thereof
|
US20050053973A1
(en)
*
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20060223114A1
(en)
*
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
US20050048512A1
(en)
*
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
US20030157561A1
(en)
*
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
US20040175756A1
(en)
*
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
US20030082630A1
(en)
*
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
EP1318195A1
(en)
*
|
2001-12-10 |
2003-06-11 |
CatchMabs B.V. |
A structure for presenting desired peptide sequences
|
AU2003243436A1
(en)
|
2002-06-06 |
2003-12-22 |
Shohei Koide |
Reconstituted polypeptides
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
WO2004092741A2
(en)
*
|
2003-04-14 |
2004-10-28 |
Montana State University |
Mapping discontinuous antibody or aptamer epitopes for protein structure determination and other applications
|
CA2524124C
(en)
|
2003-04-30 |
2014-03-25 |
Uwe Zangemeister-Wittke |
Methods for treating cancer using an immunotoxin
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
AU2004284090A1
(en)
*
|
2003-10-24 |
2005-05-06 |
Avidia, Inc. |
LDL receptor class A and EGF domain monomers and multimers
|
US20080220049A1
(en)
*
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
RU2402567C2
(ru)
|
2003-12-05 |
2010-10-27 |
Бристоль-Майерз Сквибб Компани |
Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2
|
GB0400122D0
(en)
|
2004-01-06 |
2004-02-11 |
Badrilla Ltd |
Method of quantifying binding
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
GB0417887D0
(en)
|
2004-08-11 |
2004-09-15 |
Ares Trading Sa |
Protein
|
GB0423126D0
(en)
*
|
2004-10-18 |
2004-11-17 |
Ares Trading Sa |
Protein
|
GB0426960D0
(en)
*
|
2004-12-08 |
2005-01-12 |
Ares Trading Sa |
TGR-3 like protein receptor
|
JP2008525000A
(ja)
*
|
2004-12-28 |
2008-07-17 |
アレス トレーディング エス.エー. |
統合失調症及び関連障害を治療するための組成物及び方法
|
US7749694B2
(en)
|
2004-12-31 |
2010-07-06 |
The Regents Of The University Of California |
C-type lectin fold as a scaffold for massive sequence variation
|
CA2594356C
(en)
|
2005-01-05 |
2018-07-17 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
GB0504767D0
(en)
*
|
2005-03-08 |
2005-04-13 |
Ares Trading Sa |
Lipocalin protein
|
US7833979B2
(en)
*
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US9829494B2
(en)
|
2005-12-01 |
2017-11-28 |
Adrenomed Ag |
Methods of treatment using ADM antibodies
|
US8445639B2
(en)
|
2006-05-15 |
2013-05-21 |
Avidbiotics Corporation |
Recombinant bacteriophage and methods for their use
|
US7700729B2
(en)
*
|
2006-05-15 |
2010-04-20 |
Avidbiotics Corporation |
Modified bacteriocins and methods for their use
|
DK2371842T3
(da)
*
|
2006-05-15 |
2015-10-26 |
Avidbiotics Corp |
Modificerede bakteriociner og fremgangsmåder til anvendelse heraf
|
CN101506227A
(zh)
*
|
2006-05-26 |
2009-08-12 |
怀卡托灵科有限公司 |
Ob折叠结构域
|
SI2029173T1
(sl)
|
2006-06-26 |
2016-12-30 |
Macrogenics, Inc. |
Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
|
AT503902B1
(de)
*
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
WO2008003473A2
(en)
*
|
2006-07-06 |
2008-01-10 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
WO2008023840A2
(en)
|
2006-08-25 |
2008-02-28 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
CA2666507A1
(en)
|
2006-10-16 |
2008-04-24 |
The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona A Cting For And On Behalf Of Arizona State University |
Synthetic antibodies
|
CA2666682C
(en)
|
2006-10-19 |
2014-07-08 |
Merck & Co., Inc. |
Anti-il-13r.alpha.1 antibodies and their uses thereof
|
EP2829551B1
(en)
|
2006-10-19 |
2017-12-13 |
CSL Limited |
High affinity antibody antagonists of interleukin-13 receptor alpha 1
|
WO2008088422A2
(en)
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
US20080206241A1
(en)
|
2006-11-21 |
2008-08-28 |
Kalobios Pharmaceuticals Inc. |
Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
|
EP3156415A1
(en)
|
2006-11-22 |
2017-04-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
EP2111228B1
(en)
|
2007-02-02 |
2011-07-20 |
Bristol-Myers Squibb Company |
10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
|
EP2124996A4
(en)
|
2007-02-20 |
2010-03-24 |
Merrimack Pharmaceuticals Inc |
METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
|
PL3199180T3
(pl)
|
2007-03-08 |
2022-08-08 |
Humanigen, Inc. |
Przeciwciała przeciwko epha3 do leczenia guzów litych
|
EP2118138A1
(en)
|
2007-03-12 |
2009-11-18 |
Esbatech AG |
Sequence based engineering and optimization of single chain antibodies
|
EP2076289B1
(en)
|
2007-04-13 |
2014-11-12 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
EP2145021A2
(en)
|
2007-05-17 |
2010-01-20 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
|
US8420779B2
(en)
|
2007-05-22 |
2013-04-16 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
SI2158315T1
(sl)
|
2007-06-25 |
2016-05-31 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
|
JP5506670B2
(ja)
|
2007-06-25 |
2014-05-28 |
エスバテック − ア ノバルティス カンパニー エルエルシー |
単鎖抗体の配列に基づくエンジニアリング及び最適化
|
US8921279B2
(en)
|
2007-06-26 |
2014-12-30 |
F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H |
Display of binding agents
|
US8470966B2
(en)
|
2007-08-10 |
2013-06-25 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
US8680019B2
(en)
|
2007-08-10 |
2014-03-25 |
Protelica, Inc. |
Universal fibronectin Type III binding-domain libraries
|
AU2008287426B2
(en)
|
2007-08-10 |
2014-06-26 |
Protelica, Inc. |
Universal fibronectin type III binding-domain libraries
|
CN102316888A
(zh)
*
|
2007-08-23 |
2012-01-11 |
利兰斯坦福青年大学托管委员会 |
突触发生的调控
|
WO2009028158A1
(en)
|
2007-08-24 |
2009-03-05 |
Oncotherapy Science, Inc. |
Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
|
JP2010536365A
(ja)
|
2007-08-24 |
2010-12-02 |
オンコセラピー・サイエンス株式会社 |
前立腺癌の治療及び診断の標的遺伝子のための、pkib及びnaaladl2
|
US20110152345A1
(en)
|
2007-08-24 |
2011-06-23 |
Oncotherapy Science, Inc. |
Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
|
GB2453589A
(en)
|
2007-10-12 |
2009-04-15 |
King S College London |
Protease inhibition
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
KR101686247B1
(ko)
*
|
2007-10-31 |
2016-12-14 |
메디뮨 엘엘씨 |
단백질 스캐폴드
|
CN101951954A
(zh)
|
2007-11-02 |
2011-01-19 |
诺瓦提斯公司 |
调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法
|
US9885050B2
(en)
*
|
2007-11-08 |
2018-02-06 |
The University Of Chicago |
Molecular affinity clamp technology and uses thereof
|
EP2615115A3
(en)
|
2007-11-30 |
2014-01-08 |
Glaxo Group Limited |
Antigen-binding constructs
|
US20100322930A1
(en)
*
|
2007-12-27 |
2010-12-23 |
Frank Kolbinger |
Fibronectin-based binding molecules and their use
|
EP2245062B1
(en)
|
2008-01-15 |
2012-04-25 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating bone-loss disorders using a gm-csf antagonist
|
KR20100128291A
(ko)
|
2008-02-14 |
2010-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
Egfr에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
|
AU2009239558B2
(en)
|
2008-04-21 |
2013-05-02 |
Bio-Rad Laboratories, Inc. |
Recombinant deamidated gliadin antigen
|
US20120021967A1
(en)
*
|
2008-04-23 |
2012-01-26 |
Arizona Board of Regents, A Body Corporate of the State Of Arizona Acting for and Behalf of Arizona |
Synthetic antibodies
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
EP2383292A1
(en)
|
2008-05-02 |
2011-11-02 |
Novartis AG |
Improved fibronectin-based binding molecules and uses thereof
|
EP2441447A1
(en)
|
2008-05-06 |
2012-04-18 |
Glaxo Group Limited |
Encapsulation of biologically active agents
|
JP2011520961A
(ja)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
多価フィブロネクチンをベースとする足場ドメインタンパク質
|
AU2009264566B2
(en)
|
2008-06-25 |
2014-05-08 |
Novartis Ag |
Solubility optimization of immunobinders
|
EP3629022A1
(en)
|
2008-07-25 |
2020-04-01 |
Richard W. Wagner |
Protein screening methods
|
DK2328616T3
(da)
|
2008-08-05 |
2015-07-20 |
Novartis Ag |
Sammensætninger og fremgangsmåder for antistoffer mod komplementprotein C5
|
US9433684B2
(en)
|
2008-08-19 |
2016-09-06 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
AU2009340423B2
(en)
|
2008-10-29 |
2014-07-24 |
Bg Medicine, Inc. |
Galectin-3 immunoassay
|
BRPI0919881B1
(pt)
|
2008-10-31 |
2021-09-08 |
Centocor Ortho Biotech Inc |
Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
|
US8415291B2
(en)
*
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
MX2011006483A
(es)
|
2008-12-16 |
2011-07-13 |
Novartis Ag |
Sistemas de despliegue en levadura.
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
WO2010093814A1
(en)
|
2009-02-11 |
2010-08-19 |
Kalobios Pharmaceuticals, Inc. |
Methods of treating dementia using a gm-csf antagonist
|
EP2401298A1
(en)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Antigen-binding constructs
|
US20110305693A1
(en)
|
2009-02-24 |
2011-12-15 |
Glaxo Group Limited |
Anitigen-binding constructs
|
US20110305694A1
(en)
|
2009-02-24 |
2011-12-15 |
Paul Andrew Hamblin |
Multivalent and/or multispecific rankl-binding constructs
|
AR075715A1
(es)
*
|
2009-03-05 |
2011-04-20 |
Novartis Ag |
Formulacion de anticuerpo liofilizado
|
CN102405237A
(zh)
|
2009-03-06 |
2012-04-04 |
卡罗拜奥斯制药公司 |
利用EphA3抗体治疗白血病和慢性骨髓增生性疾病
|
US8067201B2
(en)
*
|
2009-04-17 |
2011-11-29 |
Bristol-Myers Squibb Company |
Methods for protein refolding
|
CA2993053A1
(en)
|
2009-04-27 |
2010-11-04 |
Novartis Ag |
Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
|
EP2424894A1
(en)
|
2009-04-27 |
2012-03-07 |
Novartis AG |
Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
|
WO2010127186A1
(en)
|
2009-04-30 |
2010-11-04 |
Prognosys Biosciences, Inc. |
Nucleic acid constructs and methods of use
|
JP5426026B2
(ja)
|
2009-07-28 |
2014-02-26 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
非侵襲性インビボ光学イメージング方法
|
WO2011018421A1
(en)
|
2009-08-10 |
2011-02-17 |
Morphosys Ag |
Novel screening strategies for the identification of binders
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
JP5733784B2
(ja)
*
|
2009-09-24 |
2015-06-10 |
国立大学法人埼玉大学 |
cDNA/mRNA−タンパク質連結体の効率的合成法
|
EP2494070A2
(en)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
US9139825B2
(en)
|
2009-10-30 |
2015-09-22 |
Novartis Ag |
Universal fibronectin type III bottom-side binding domain libraries
|
US20120282276A1
(en)
|
2009-11-05 |
2012-11-08 |
The Regents Of The University Of Michigan |
Biomarkers predictive of progression of fibrosis
|
EP2506861A1
(en)
|
2009-12-02 |
2012-10-10 |
Amgen Inc. |
Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
JP5972793B2
(ja)
|
2009-12-23 |
2016-08-17 |
アフィニティ バイオサイエンス ピーティーワイ リミテッド |
タンパク質ディスプレイ
|
JP5850860B2
(ja)
|
2010-01-28 |
2016-02-03 |
グラクソ グループ リミテッドGlaxo Group Limited |
Cd127結合タンパク質
|
KR20120125357A
(ko)
|
2010-02-10 |
2012-11-14 |
노파르티스 아게 |
근육 성장을 위한 방법 및 화합물
|
WO2011103105A1
(en)
|
2010-02-18 |
2011-08-25 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domain proteins that bind il-23
|
EP3153521B1
(en)
|
2010-03-26 |
2019-09-04 |
Trustees of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10787701B2
(en)
|
2010-04-05 |
2020-09-29 |
Prognosys Biosciences, Inc. |
Spatially encoded biological assays
|
CA2794522C
(en)
|
2010-04-05 |
2019-11-26 |
Prognosys Biosciences, Inc. |
Spatially encoded biological assays
|
US20190300945A1
(en)
|
2010-04-05 |
2019-10-03 |
Prognosys Biosciences, Inc. |
Spatially Encoded Biological Assays
|
BR112012026216B1
(pt)
|
2010-04-13 |
2022-07-26 |
Bristol-Myers Squibb Company |
Proteínas com domínio "scaffold" baseado em fibronectina que se ligam à pcsk9, seu uso, bem como composição farmacêutica compreendendo as mesmas
|
CA2795325A1
(en)
|
2010-04-13 |
2011-10-20 |
Medimmune, Llc |
Fibronectin type iii domain-based multimeric scaffolds
|
ES2923567T3
(es)
|
2010-04-30 |
2022-09-28 |
Janssen Biotech Inc |
Composiciones del dominio de fibronectina estabilizadas, métodos y usos
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
EP4234698A3
(en)
|
2010-05-06 |
2023-11-08 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
KR20130066631A
(ko)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
치료적 저밀도 지단백질-관련 단백질 6 (lrp6) 다가 항체에 대한 조성물 및 사용 방법
|
CN102939538A
(zh)
|
2010-05-07 |
2013-02-20 |
霍夫曼-拉罗奇有限公司 |
用于离体检测细胞的诊断方法
|
EP2576615B1
(en)
|
2010-05-26 |
2016-03-30 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
NZ605400A
(en)
|
2010-07-09 |
2015-05-29 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors
|
BR112013004012B1
(pt)
|
2010-08-20 |
2021-03-23 |
Novartis Ag |
Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
WO2012061759A2
(en)
|
2010-11-05 |
2012-05-10 |
Morphotek Inc. |
Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
|
EP3211009A1
(en)
|
2010-11-23 |
2017-08-30 |
Glaxo Group Limited |
Antigen binding proteins to oncostatin m (osm)
|
EP2643351A1
(en)
|
2010-11-24 |
2013-10-02 |
Glaxo Group Limited |
Multispecific antigen binding proteins targeting hgf
|
WO2012088006A1
(en)
|
2010-12-22 |
2012-06-28 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domain proteins that bind il-23
|
EP2694709B1
(en)
|
2011-04-08 |
2016-09-14 |
Prognosys Biosciences, Inc. |
Peptide constructs and assay systems
|
ES2876421T3
(es)
|
2011-04-13 |
2021-11-12 |
Bristol Myers Squibb Co |
Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos
|
GB201106254D0
(en)
|
2011-04-13 |
2011-05-25 |
Frisen Jonas |
Method and product
|
WO2012140627A1
(en)
|
2011-04-15 |
2012-10-18 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
US20140187488A1
(en)
|
2011-05-17 |
2014-07-03 |
Bristol-Myers Squibb Company |
Methods for maintaining pegylation of polypeptides
|
EP3318880B1
(en)
|
2011-05-17 |
2020-12-16 |
Bristol-Myers Squibb Company |
Improved methods for the selection of binding proteins
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
HRP20231066T1
(hr)
|
2011-05-27 |
2023-10-27 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - vezujući proteini
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
EP2726652B1
(en)
|
2011-06-29 |
2016-09-28 |
Affinity Biosciences Pty Ltd |
Method of protein display
|
EP2726099B1
(en)
|
2011-07-01 |
2018-07-25 |
Novartis AG |
Method for treating metabolic disorders
|
EP2731970B1
(en)
|
2011-07-15 |
2018-11-28 |
MorphoSys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
JP6094486B2
(ja)
|
2011-08-11 |
2017-03-15 |
小野薬品工業株式会社 |
Pd−1アゴニストからなる自己免疫疾患治療剤
|
KR102142385B1
(ko)
|
2011-09-27 |
2020-08-10 |
얀센 바이오테크 인코포레이티드 |
대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드
|
KR102434073B1
(ko)
|
2011-10-11 |
2022-08-18 |
비엘라 바이오, 인크. |
Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
|
EP2766497A1
(en)
|
2011-10-13 |
2014-08-20 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
CN104053670A
(zh)
|
2011-10-31 |
2014-09-17 |
百时美施贵宝公司 |
具有降低的免疫原性的纤连蛋白结合域
|
WO2013067355A1
(en)
|
2011-11-04 |
2013-05-10 |
Novartis Ag |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
ES2707878T3
(es)
|
2011-11-16 |
2019-04-05 |
Adrenomed Ag |
Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para regular el equilibrio de líquidos en un paciente que presenta una enfermedad crónica o aguda
|
EP2594587B1
(en)
|
2011-11-16 |
2014-05-21 |
AdrenoMed AG |
Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
|
BR122019027917B1
(pt)
|
2011-11-16 |
2023-05-09 |
Adrenomed Ag |
Uso de um anticorpo anti-adrenomedulina (adm) enxertado em cdr humano ou humanizado ou fragmento de anticorpo anti-adm do mesmo
|
DK2780717T3
(da)
|
2011-11-16 |
2017-02-13 |
Sphingotec Gmbh |
Adrenomedullinassays og fremgangsmåder til bestemmelse af modent adrenomedullin
|
DK2780370T3
(da)
|
2011-11-16 |
2019-10-28 |
Adrenomed Ag |
Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-ikke-ig skelet til anvendelse i terapi af en akut sygdom eller akut tilstand af en patient til at stabilisere kredsløbet
|
SI3553084T1
(sl)
|
2011-11-16 |
2023-05-31 |
Adrenomed Ag |
Protitelo anti-adrenomedulina (ADM) ali fragment protitelesa anti-ADM ali anti-ADM non-IG ogrodje za preprečevanje ali zmanjšanje disfunkcije organa ali odpovedi organa pri pacientu s kronično ali akutno boleznijo ali akutnim stanjem
|
WO2013084147A2
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
JP2015500829A
(ja)
|
2011-12-05 |
2015-01-08 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体3(her3)のドメインiiに対するher3の抗体
|
EP2788760B1
(en)
|
2011-12-05 |
2017-02-15 |
Bio-rad Laboratories, Inc. |
Recombinant deamidated gliadin antigen
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
ES2728278T3
(es)
|
2011-12-21 |
2019-10-23 |
Novartis Ag |
Composiciones que comprenden anticuerpos dirigidos al factor P y C5
|
LT2802606T
(lt)
|
2012-01-10 |
2018-10-10 |
Biogen Ma Inc. |
Terapinių molekulių transporto per kraujo-smegenų barjerą padidinimas
|
EP2809800A1
(en)
|
2012-01-30 |
2014-12-10 |
VIB vzw |
Means and method for diagnosis and treatment of alzheimer's disease
|
SG10201708562VA
(en)
|
2012-02-13 |
2017-12-28 |
Agency Science Tech & Res |
IL-1β Neutralizing Human Monoclonal Antibodies
|
CN103308673B
(zh)
|
2012-03-08 |
2017-05-31 |
思芬构技术有限公司 |
用于预测雌性对象中发生心血管事件的风险的方法
|
CN103308689B
(zh)
|
2012-03-08 |
2017-04-12 |
思芬构技术有限公司 |
用于预测雌性对象中患上癌症的风险或诊断癌症的方法
|
CN103308670B
(zh)
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
WO2014039983A1
(en)
|
2012-09-07 |
2014-03-13 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
LT2895503T
(lt)
|
2012-09-13 |
2019-07-25 |
Bristol-Myers Squibb Company |
Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie sąveikauja su miostatinu
|
PL3361260T3
(pl)
|
2012-10-02 |
2020-12-14 |
Sphingotec Gmbh |
Sposób diagnozowania lub monitorowania czynności nerek lub diagnozowania dysfunkcji nerek
|
US9725512B2
(en)
|
2012-11-08 |
2017-08-08 |
Hoffmann-La Roche Inc. |
HER3 antibodies binding to the beta-hairpin of HER3
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
EP3851454A1
(en)
|
2012-12-05 |
2021-07-21 |
Novartis AG |
Compositions and methods for antibodies targeting epo
|
RU2677895C2
(ru)
|
2013-01-08 |
2019-01-22 |
Сфинготек Гмбх |
Уровни гормона роста натощак в качестве прогностического маркера сердечно-сосудистого риска
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
EP2953968B1
(en)
|
2013-02-06 |
2018-07-25 |
Bristol-Myers Squibb Company |
Fibronectin type iii domain proteins with enhanced solubility
|
CA2897682C
(en)
|
2013-02-08 |
2023-03-14 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
EP3617220B1
(en)
|
2013-02-12 |
2021-03-24 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
JP6416793B2
(ja)
|
2013-02-28 |
2018-10-31 |
カプリオン プロテオミクス インコーポレーテッド |
結核のバイオマーカー及びその使用
|
US20160152686A1
(en)
|
2013-03-13 |
2016-06-02 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
|
EP2970468B1
(en)
|
2013-03-13 |
2021-07-07 |
Novartis AG |
Notch2 binding molecules for treating respiratory diseases
|
EP3611189A1
(en)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antibodies against notch 3
|
EP3623380A1
(en)
|
2013-03-15 |
2020-03-18 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CN105358984B
(zh)
|
2013-03-15 |
2020-02-18 |
普罗格诺西斯生物科学公司 |
用于检测肽/mhc/tcr结合的方法
|
US9157910B2
(en)
|
2013-03-15 |
2015-10-13 |
Abbott Laboratories |
Assay with increased dynamic range
|
US9005901B2
(en)
|
2013-03-15 |
2015-04-14 |
Abbott Laboratories |
Assay with internal calibration
|
RU2673455C2
(ru)
|
2013-03-20 |
2018-11-27 |
Сфинготек Гмбх |
Адреномедуллин для направленной терапии по снижению кровяного давления
|
WO2014179983A1
(zh)
*
|
2013-05-10 |
2014-11-13 |
北京华金瑞清生物医药技术有限公司 |
一种改造非抗体类蛋白产生结合分子的方法、所产生的产品和一种长效glp-1受体激动剂
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
US9879313B2
(en)
|
2013-06-25 |
2018-01-30 |
Prognosys Biosciences, Inc. |
Methods and systems for determining spatial patterns of biological targets in a sample
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
SG10201801063TA
(en)
|
2013-08-14 |
2018-04-27 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
US10059937B2
(en)
|
2013-09-27 |
2018-08-28 |
The Board Of Trustees Of The University Of Illinois |
Method and kit for generating high affinity binding agents
|
CA2926215A1
(en)
|
2013-10-06 |
2015-04-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified pseudomonas exotoxin a
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
WO2015070037A2
(en)
|
2013-11-08 |
2015-05-14 |
Prognosys Biosciences, Inc. |
Polynucleotide conjugates and methods for analyte detection
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
CN106661107B
(zh)
|
2013-12-24 |
2021-12-24 |
杨森制药公司 |
抗vista抗体及片段
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
US10442851B2
(en)
|
2014-03-20 |
2019-10-15 |
Bristol-Myers Squibb Company |
Serum albumin-binding fibronectin type III domains
|
EP3119803B1
(en)
|
2014-03-20 |
2019-09-11 |
Bristol-Myers Squibb Company |
Stabilized fibronectin based scaffold molecules
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
WO2016004055A1
(en)
|
2014-07-03 |
2016-01-07 |
Yale University |
Dickkopf2 (Dkk2) Inhibition Suppresses Tumor Formation
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
EP3194437B1
(en)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Angiopoietin-like 4 (angptl4) antibodies and methods of use
|
DK3177642T3
(da)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US20160097781A1
(en)
|
2014-10-01 |
2016-04-07 |
Sphingotec Gmbh |
Method for stratifying a female subject for hormone replacement therapy
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
HUE049982T2
(hu)
|
2014-11-14 |
2020-11-30 |
Hoffmann La Roche |
TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
|
JP6701217B2
(ja)
|
2014-11-25 |
2020-05-27 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
生物学的製剤の18f−放射性標識方法および組成物
|
KR102632418B1
(ko)
|
2014-11-25 |
2024-01-31 |
브리스톨-마이어스 스큅 컴퍼니 |
영상화를 위한 신규 pd-l1 결합 폴리펩티드
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
CN107427573B
(zh)
|
2014-12-24 |
2022-12-27 |
耐克西缪恩有限公司 |
用于免疫疗法的纳米颗粒组合物和方法
|
IL303972A
(en)
|
2015-04-08 |
2023-08-01 |
Novartis Ag |
CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
|
EP4321627A3
(en)
|
2015-04-10 |
2024-04-17 |
10x Genomics Sweden AB |
Spatially distinguished, multiplex nucleic acid analysis of biological specimens
|
KR20170138558A
(ko)
|
2015-04-24 |
2017-12-15 |
비브 헬스케어 유케이 (넘버5) 리미티드 |
Hiv 융합을 표적으로 하는 폴리펩티드
|
WO2016170023A1
(en)
|
2015-04-24 |
2016-10-27 |
Sphingotec Gmbh |
A method for predicting the risk of incidence of chronic kidney disease
|
CN115925961A
(zh)
|
2015-05-28 |
2023-04-07 |
生物辐射实验室股份有限公司 |
亲和配体及其相关方法
|
PE20180041A1
(es)
|
2015-06-05 |
2018-01-09 |
Novartis Ag |
Anticuerpos dirigidos a la proteina morfogenetica osea (bmp9) y metodos a partir de estos
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
EP3331914A1
(en)
|
2015-08-03 |
2018-06-13 |
Novartis AG |
Methods of treating fgf21-associated disorders
|
DK3347377T3
(da)
|
2015-09-09 |
2021-05-10 |
Novartis Ag |
Tymisk stromal lymfopoietin (TSLP)-bindende antistoffer og fremgangsmåder til anvendelse af antistofferne
|
TN2018000076A1
(en)
|
2015-09-09 |
2019-07-08 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
WO2017048709A1
(en)
|
2015-09-14 |
2017-03-23 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Generating recominant affinity reagents with arrayed targets
|
CN108884147B
(zh)
|
2015-09-23 |
2024-02-27 |
百时美施贵宝公司 |
结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
|
JP6893504B2
(ja)
|
2015-09-23 |
2021-06-23 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
速い解離速度を有する血清アルブミン結合フィブロネクチンタイプiiiドメイン
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
MY192202A
(en)
|
2015-10-02 |
2022-08-06 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
PE20240096A1
(es)
|
2015-10-02 |
2024-01-18 |
Hoffmann La Roche |
Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
|
JP7074665B2
(ja)
|
2015-10-07 |
2022-05-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体に対する四価の二重特異性抗体発明の分野
|
WO2017074774A1
(en)
|
2015-10-28 |
2017-05-04 |
Yale University |
Humanized anti-dkk2 antibody and uses thereof
|
EP3371311B1
(en)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
KR20180081608A
(ko)
|
2015-11-19 |
2018-07-16 |
아스클리픽스 테라퓨틱스, 엘엘씨. |
항-혈관형성, 항-림프관신생, 및 항-부종성 특성을 가진 펩티드 및 나노입자 제제
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
CA3013551A1
(en)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Clec9a binding agents and use thereof
|
EP3413910A1
(en)
|
2016-02-12 |
2018-12-19 |
Janssen Pharmaceutica NV |
Anti-vista (b7h5) antibodies
|
SG11201805941WA
(en)
|
2016-02-17 |
2018-09-27 |
Novartis Ag |
Tgfbeta 2 antibodies
|
WO2017153402A1
(en)
|
2016-03-07 |
2017-09-14 |
Vib Vzw |
Cd20 binding single domain antibodies
|
WO2017161169A1
(en)
|
2016-03-17 |
2017-09-21 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-py1235-met immunological binding reagent
|
CA3016563A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
US20190218515A1
(en)
|
2016-04-13 |
2019-07-18 |
Vivia Biotech, S.L. |
Ex vivo bite-activated t cells
|
UA125382C2
(uk)
|
2016-04-15 |
2022-03-02 |
Імьюнекст Інк. |
Антитіла проти людського vista та їх застосування
|
US20190145981A1
(en)
|
2016-04-21 |
2019-05-16 |
Sphingotec Therapeutics Gmbh |
Methods for determining dpp3 and therapeutic methods
|
JP7138567B2
(ja)
|
2016-04-27 |
2022-09-16 |
ノバルティス アーゲー |
成長分化因子15に対する抗体およびそれらの使用
|
CN109071652B
(zh)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
CA3023881A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Therapeutic targeting of non-cellular structures
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
CN109562195A
(zh)
|
2016-06-01 |
2019-04-02 |
百时美施贵宝公司 |
用pd-l1结合多肽进行pet成像
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
WO2017210598A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Compositions and methods for treating an articular disorder
|
WO2017216724A1
(en)
|
2016-06-15 |
2017-12-21 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
|
MA45493A
(fr)
|
2016-06-27 |
2019-05-01 |
Aicuris Anti Infective Cures Gmbh |
Inhibiteurs d'entrée de hcmv.
|
CA3030214A1
(en)
|
2016-07-08 |
2018-01-11 |
Sphingotec Gmbh |
Adrenomedullin for assessing congestion in a subject with acute heart failure
|
EP3512875A2
(en)
|
2016-09-15 |
2019-07-24 |
Quadrucept Bio Limited |
Multimers, tetramers&octamers
|
WO2018057955A1
(en)
|
2016-09-23 |
2018-03-29 |
Elstar Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
KR20190066040A
(ko)
|
2016-10-04 |
2019-06-12 |
아스클리픽스 테라퓨틱스, 인크. |
Tie2 신호전달을 활성화시키기 위한 화합물 및 방법
|
EP3309550A1
(en)
|
2016-10-12 |
2018-04-18 |
sphingotec GmbH |
Method for the detection of apolipoprotein e4
|
WO2018077893A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
US10611823B2
(en)
|
2016-12-14 |
2020-04-07 |
Hanssen Biotech, Inc |
CD137 binding fibronectin type III domains
|
AU2017378226A1
(en)
|
2016-12-14 |
2019-06-20 |
Janssen Biotech, Inc. |
CD8A-binding fibronectin type III domains
|
US10597438B2
(en)
|
2016-12-14 |
2020-03-24 |
Janssen Biotech, Inc. |
PD-L1 binding fibronectin type III domains
|
US20200299372A1
(en)
|
2016-12-16 |
2020-09-24 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
IL267538B1
(en)
|
2016-12-23 |
2024-01-01 |
Novartis Ag |
Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
|
TW201829469A
(zh)
|
2017-01-03 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
包含抗4-1bb純系20h4.9之雙特異性抗原結合分子
|
JP2020505955A
(ja)
|
2017-02-06 |
2020-02-27 |
オリオンズ バイオサイエンス インコーポレイテッド |
標的化改変型インターフェロン及びその使用
|
AU2018216032B2
(en)
|
2017-02-06 |
2022-04-07 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
CA3050601A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzm |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
MX2019009498A
(es)
|
2017-02-08 |
2019-10-02 |
Novartis Ag |
Anticuerpos mimeticos de fgf21 y usos de los mismos.
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
KR102628323B1
(ko)
|
2017-03-24 |
2024-01-22 |
노바르티스 아게 |
심장질환 예방 및 치료 방법
|
EP3601345A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
JP7205995B2
(ja)
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性tnf受容体に対する二重特異性抗原結合分子
|
RU2766234C2
(ru)
|
2017-04-04 |
2022-02-10 |
Ф. Хоффманн-Ля Рош Аг |
Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
JP2020517256A
(ja)
|
2017-04-19 |
2020-06-18 |
エルスター セラピューティクス, インコーポレイテッド |
多重特異性分子およびその使用
|
AU2018260545B2
(en)
|
2017-04-28 |
2023-11-23 |
Marengo Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
BR112019024966A2
(pt)
|
2017-05-30 |
2020-06-23 |
Sphingotec Gmbh |
Método para diagnosticar ou monitorar a função renal ou diagnosticar a disfunção renal
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
EP3638300A4
(en)
*
|
2017-06-16 |
2021-06-23 |
Protelica, Inc. |
FIBRONECTIN-BINDING CHEMICAL ANTIGEN RECEPTORS AND METHODS OF USE
|
US20200181271A1
(en)
|
2017-06-28 |
2020-06-11 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
WO2019028427A1
(en)
|
2017-08-03 |
2019-02-07 |
Asclepix Therapeutics, Llc. |
METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
KR20200088302A
(ko)
|
2017-09-25 |
2020-07-22 |
아드레노메드 아게 |
질병의 증상의 치료 또는 예방에 사용하기 위한 항-아드레노메둘린 (adm) 결합제
|
BR112020005682A2
(pt)
|
2017-10-18 |
2020-10-20 |
Adrenomed Ag |
monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm)
|
EP3701266A1
(en)
|
2017-10-24 |
2020-09-02 |
sphingotec GmbH |
Selenoprotein p for prediction of a first cardiovascular event
|
SG11202002594PA
(en)
|
2017-10-25 |
2020-04-29 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
EP3703821A2
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Bispecific 2+1 contorsbodies
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
EP3713965A1
(en)
|
2017-11-22 |
2020-09-30 |
Novartis AG |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
JP7348899B2
(ja)
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス,インコーポレーテッド |
多重特異性分子及びその使用
|
EP3728310A1
(en)
|
2017-12-18 |
2020-10-28 |
VIIV Healthcare UK (No.5) Limited |
Antigen binding polypeptides
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
CA3090406A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
CN111902721A
(zh)
|
2018-02-08 |
2020-11-06 |
斯弗因高泰克有限公司 |
用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用
|
WO2019165017A1
(en)
|
2018-02-23 |
2019-08-29 |
The University Of Chicago |
Methods and composition involving thermophilic fibronectin type iii (fn3) monobodies
|
US20210238280A1
(en)
|
2018-03-14 |
2021-08-05 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
WO2019197600A1
(en)
|
2018-04-13 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
EP3569614A1
(en)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
EP3586865A1
(en)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
EP3823979A1
(en)
*
|
2018-07-20 |
2021-05-26 |
AiCuris GmbH & Co. KG |
Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
|
US20220242957A1
(en)
|
2018-09-27 |
2022-08-04 |
Marengo Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
MX2021003548A
(es)
|
2018-10-01 |
2021-05-27 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
AR117343A1
(es)
|
2018-12-18 |
2021-07-28 |
Novartis Ag |
AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
|
MX2021007467A
(es)
|
2018-12-20 |
2021-08-05 |
Sphingotec Gmbh |
Selenoproteina p en insuficiencia cardiaca.
|
JP2022513495A
(ja)
|
2018-12-21 |
2022-02-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
腫瘍標的化スーパーアゴニストcd28抗原結合分子
|
EP3897686A2
(en)
|
2018-12-21 |
2021-10-27 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof
|
CN113286821A
(zh)
|
2018-12-21 |
2021-08-20 |
豪夫迈·罗氏有限公司 |
靶向肿瘤的激动性cd28抗原结合分子
|
WO2020168059A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
CN113661175A
(zh)
|
2019-02-15 |
2021-11-16 |
整体分子公司 |
包含共同轻链的抗体及其用途
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
CA3130508A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
CN113677403A
(zh)
|
2019-04-12 |
2021-11-19 |
豪夫迈·罗氏有限公司 |
包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
|
AU2020304813A1
(en)
|
2019-06-26 |
2022-01-06 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding CEA and 4-1BBL
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
WO2021006199A1
(ja)
|
2019-07-05 |
2021-01-14 |
小野薬品工業株式会社 |
Pd-1/cd3二重特異性タンパク質による血液がん治療
|
JPWO2021025140A1
(da)
|
2019-08-08 |
2021-02-11 |
|
|
BR112022001417A2
(pt)
|
2019-08-15 |
2022-05-24 |
Sphingotec Gmbh |
Método para diagnóstico ou monitoramento de função renal ou diagnóstico de disfunção renal em pacientes pediátricos
|
CA3148275A1
(en)
|
2019-08-30 |
2021-03-04 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for treatment of shock
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
US11628222B2
(en)
|
2019-10-14 |
2023-04-18 |
Aro Biotherapeutics Company |
CD71 binding fibronectin type III domains
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
EP3871689A1
(en)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
|
CA3172349A1
(en)
|
2020-02-27 |
2021-09-02 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
|
CA3169447A1
(en)
|
2020-02-27 |
2021-09-02 |
Andreas Bergmann |
Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
|
WO2021170876A1
(en)
|
2020-02-27 |
2021-09-02 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
JP2023515633A
(ja)
|
2020-02-28 |
2023-04-13 |
ブリストル-マイヤーズ スクイブ カンパニー |
放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
|
EP3922993A1
(en)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
JP2023518731A
(ja)
|
2020-03-16 |
2023-05-08 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
コロナウイルスに感染した患者におけるdpp3
|
AU2021238591A1
(en)
|
2020-03-16 |
2022-11-17 |
Adrenomed Ag |
Pro-Adrenomedullin or fragment thereof in patients infected with Corona virus and treatments with binder against adrenomedullin
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
JP2023523011A
(ja)
|
2020-04-24 |
2023-06-01 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞関連のがん細胞に結合する多機能性分子およびその使用
|
WO2021228956A1
(en)
|
2020-05-12 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
MX2022015795A
(es)
|
2020-06-23 |
2023-01-24 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que se dirigen a her2.
|
WO2021260064A1
(en)
|
2020-06-25 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
CA3190755A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
CN116761818A
(zh)
|
2020-08-26 |
2023-09-15 |
马伦戈治疗公司 |
检测trbc1或trbc2的方法
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
EP4244254A1
(en)
|
2020-11-16 |
2023-09-20 |
F. Hoffmann-La Roche AG |
Combination therapy with fap-targeted cd40 agonists
|
EP4023218A1
(en)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Combination therapy for patients having acute and/or persistent dyspnea
|
JP2023554351A
(ja)
|
2020-12-16 |
2023-12-27 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
新規の徐放性プロドラッグ
|
JP2024503826A
(ja)
|
2021-01-06 |
2024-01-29 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1-lag3二重特異性抗体及びcd20 t細胞二重特異性抗体を用いる併用療法
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
EP4304730A1
(en)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Novel darpin based cd33 engagers
|
EP4305063A1
(en)
|
2021-03-09 |
2024-01-17 |
Molecular Partners AG |
Protease cleavable prodrugs
|
CA3211368A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
CN117529664A
(zh)
|
2021-06-18 |
2024-02-06 |
思芬构技术有限公司 |
用于预测脓毒症和脓毒性休克的方法
|
KR20240041912A
(ko)
|
2021-06-29 |
2024-04-01 |
베리솔 게엠베하 |
체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
AU2022317820A1
(en)
|
2021-07-28 |
2023-12-14 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
TW202340248A
(zh)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
促效性ltbr抗體及包含其之雙特異性抗體
|
WO2023170296A1
(en)
|
2022-03-11 |
2023-09-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Nucleic acid system to specifically reprogram b and t cells and uses thereof
|
WO2023175035A1
(en)
|
2022-03-15 |
2023-09-21 |
Adrenomed Ag |
Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
WO2024023368A1
(en)
|
2022-07-29 |
2024-02-01 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056861A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for stimulating nk cells and use thereof
|
WO2024077118A2
(en)
|
2022-10-06 |
2024-04-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|